Cue Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CUE Nasdaq 2836 www.cuebiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cue Biopharma, Inc.

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - Jul 16th, 2025 6:00 am
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - Jul 1st, 2025 2:05 pm
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - Jun 24th, 2025 2:48 pm
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2025 3:10 pm
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - May 12th, 2025 2:05 pm
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - May 8th, 2025 6:00 am
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - May 5th, 2025 8:00 am
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - May 2nd, 2025 8:00 am
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - May 1st, 2025 8:01 am
Boehringer, Oxford University and Cumulus to explore brain activity in BPD - Apr 30th, 2025 7:30 am
Boehringer and Cue Biopharma to develop autoimmune therapies - Apr 16th, 2025 2:58 am
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Apr 14th, 2025 8:23 pm
Cue Biopharma Announces Proposed Public Offering - Apr 14th, 2025 3:05 pm
Cue Biopharma to Host Business Update Call and Webcast - Apr 14th, 2025 3:02 pm
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Apr 14th, 2025 3:00 pm
Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Apr 2nd, 2025 5:39 am
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Mar 31st, 2025 3:15 pm
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Mar 31st, 2025 2:20 pm
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Mar 17th, 2025 3:33 am
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 29th, 2024 2:30 pm